pSivida Corp. (PSDV) ,,,,, un GIOIELLO !!! (1 Viewer)
- Creatore Discussione acqua+
- Data di Inizio
acqua+
ONDA NITRICA
PROFILO
pSivida Corp., together with its subsidiaries, develops drug delivery products in the healthcare sector, primarily for ophthalmology and oncology. It develops products utilizing its proprietary technologies, including Durasert, BioSilicon, and CODRUG. The company’s products include Vitrasert for the treatment of AIDS-related cytomegalovirus retinitis; and Retisert for the treatment of uveitis. Its products also include Iluvien, a Phase III clinical trial product for the treatment of diabetic macular edema; and Medidur and Iluvien, which are under pre-clinical trials to treat retinitis pigmentosa and age-related macular degeneration. In addition, pSivida Corp. owns the rights to develop and commercialize a modified form of silicon, known as BioSilicon, which has therapeutic applications for treatment of cancer. Its lead BioSilicon product is BrachySil, which is in Phase II clinical trial for the treatment of pancreatic cancer. The company primarily operates in Australia, the United Kingdom, and the United States. It has strategic collaborations with Chiron Vision Corporation; Bausch & Lomb Incorporated; Alimera Sciences, Inc.; and Pfizer, Inc. The company, formerly known as pSivida Limited, was founded in 1987 and is based in Watertown, Massachusetts.
pSivida Corp., together with its subsidiaries, develops drug delivery products in the healthcare sector, primarily for ophthalmology and oncology. It develops products utilizing its proprietary technologies, including Durasert, BioSilicon, and CODRUG. The company’s products include Vitrasert for the treatment of AIDS-related cytomegalovirus retinitis; and Retisert for the treatment of uveitis. Its products also include Iluvien, a Phase III clinical trial product for the treatment of diabetic macular edema; and Medidur and Iluvien, which are under pre-clinical trials to treat retinitis pigmentosa and age-related macular degeneration. In addition, pSivida Corp. owns the rights to develop and commercialize a modified form of silicon, known as BioSilicon, which has therapeutic applications for treatment of cancer. Its lead BioSilicon product is BrachySil, which is in Phase II clinical trial for the treatment of pancreatic cancer. The company primarily operates in Australia, the United Kingdom, and the United States. It has strategic collaborations with Chiron Vision Corporation; Bausch & Lomb Incorporated; Alimera Sciences, Inc.; and Pfizer, Inc. The company, formerly known as pSivida Limited, was founded in 1987 and is based in Watertown, Massachusetts.
acqua+
ONDA NITRICA
acqua+
ONDA NITRICA
Rindomenceslao
Forumer storico
acqua..tu cosa fai? entri ora o hai già comprato?
acqua+
ONDA NITRICA
settimana scorsa ho preso qlc ,,,, ma, con i volumi che scambia,,,,
facendo lo spilorcio ,,,, ho portato a casa poca roba
oggi ,,, cambio registro ,,,, acq. al meglio
VEDO i 10 $ ,,,, a breve
acqua+
ONDA NITRICA
la + semplice
chi le ha ,,,, se le tiene
peraltro, nell'ultima settimana i vol. sono aumentati ,,, ieri, x3 la media giorn.
acqua+
ONDA NITRICA
,,, e oggi, il CEO ,,, parla
BOSTON--(BUSINESS WIRE)--pSivida Corp, (NASDAQ:PSDV - News)(ASX:PSD - News)(FFSI), a leading drug delivery company, today announced it will webcast a live presentation at the Rodman & Renshaw Annual Health Care Conference in New York, September 10. Dr. Paul Ashton, president and chief executive officer, will present at 12:30 p.m. Eastern time.
BOSTON--(BUSINESS WIRE)--pSivida Corp, (NASDAQ:PSDV - News)(ASX:PSD - News)(FF
SI), a leading drug delivery company, today announced it will webcast a live presentation at the Rodman & Renshaw Annual Health Care Conference in New York, September 10. Dr. Paul Ashton, president and chief executive officer, will present at 12:30 p.m. Eastern time.acqua+
ONDA NITRICA
Bell'articolino 
The human eye is a truly amazing instrument. But one of its great strengths - its relative isolation from the rest of the body - is also a real problem for the treatment of eye diseases.
Delivering drugs that can treat problems at the back of the eye, such as macular degeneration, is particularly difficult.
Large and possibly toxic doses are needed when they are delivered through eye drops or intravenously.
Which is where Australian listed drug delivery company pSivida comes in.
Chief executive Dr Paul Ashton said he was "very encouraged" by a recent 12-month safety and efficacy study of its Iluvien product.
The key point about Iluvien is not the drug it contains -- well-known corticosteroid FA (fluocinolone acetonide) -- but in the manner of delivery.
The drug is contained in a tiny, slow-release device that can fit inside a needle. It is injected into the eye where it releases a very low dose of the drug over several years.
The 12-month study produced no adverse effects for low-dose patients while 23.5 per cent of high-dose patients recorded a rise in intraocular pressure.
Those figures are an improvement on earlier results recorded by Retisert, a larger insert developed by pSivida which is surgically implanted into the eye.
pSivida is also working on a nanotechnology delivery system which would be even smaller again.
Reducing side-effects is one thing, but it is treating the debilitating effect of diseases such as diabetic macular edema that is the very positive flip side.
Dr Ashton said many macular degeneration sufferers got a marked improvement.
A larger Phase 3 trial produced an improvement of 15 letters or better on a standard eye chart for 27.3 per cent on a higher dose and 23.1 per cent for the lower dose.
That sort of marked eyesight improvement is particularly important in treating patients with diabetes, who can be quite young when their vision is first affected.
One early trial patient, a young diabetic, went from being close to legally blind to getting back 20/40 eyesight.
"The main alternative treatment is with a laser and this delivery method produces much better results than that," said Dr Ashton.
The company hopes to file a new drug application with the US Food and Drug Administration next year.
Despite its innovative drug delivery technology, like most life sciences companies pSivida has come through a rocky patch on the ASX.
It licensed the only two FDA-approved, back-of-the-eye treatments for chronic eye disease to Bausch & Lomb while licensing partner Alimera Sciences is progressing the diabetic macular edema treatment.
Major shareholder Pfizer has the rights for all other opthalmic applications, which could be significant given the potential to treat other back-of-the-eye diseases.
Dr Ashton said the company was fortunate to have no debt with the prospect of significant royalty income in the short to medium term.
Last year pSivida raised $82 million from partner Alimera in exchange for increasing its equity stake in future treatment profits to 80 per cent.
The human eye is a truly amazing instrument. But one of its great strengths - its relative isolation from the rest of the body - is also a real problem for the treatment of eye diseases.
Delivering drugs that can treat problems at the back of the eye, such as macular degeneration, is particularly difficult.
Large and possibly toxic doses are needed when they are delivered through eye drops or intravenously.
Which is where Australian listed drug delivery company pSivida comes in.
Chief executive Dr Paul Ashton said he was "very encouraged" by a recent 12-month safety and efficacy study of its Iluvien product.
The key point about Iluvien is not the drug it contains -- well-known corticosteroid FA (fluocinolone acetonide) -- but in the manner of delivery.
The drug is contained in a tiny, slow-release device that can fit inside a needle. It is injected into the eye where it releases a very low dose of the drug over several years.
The 12-month study produced no adverse effects for low-dose patients while 23.5 per cent of high-dose patients recorded a rise in intraocular pressure.
Those figures are an improvement on earlier results recorded by Retisert, a larger insert developed by pSivida which is surgically implanted into the eye.
pSivida is also working on a nanotechnology delivery system which would be even smaller again.
Reducing side-effects is one thing, but it is treating the debilitating effect of diseases such as diabetic macular edema that is the very positive flip side.
Dr Ashton said many macular degeneration sufferers got a marked improvement.
A larger Phase 3 trial produced an improvement of 15 letters or better on a standard eye chart for 27.3 per cent on a higher dose and 23.1 per cent for the lower dose.
That sort of marked eyesight improvement is particularly important in treating patients with diabetes, who can be quite young when their vision is first affected.
One early trial patient, a young diabetic, went from being close to legally blind to getting back 20/40 eyesight.
"The main alternative treatment is with a laser and this delivery method produces much better results than that," said Dr Ashton.
The company hopes to file a new drug application with the US Food and Drug Administration next year.
Despite its innovative drug delivery technology, like most life sciences companies pSivida has come through a rocky patch on the ASX.
It licensed the only two FDA-approved, back-of-the-eye treatments for chronic eye disease to Bausch & Lomb while licensing partner Alimera Sciences is progressing the diabetic macular edema treatment.
Major shareholder Pfizer has the rights for all other opthalmic applications, which could be significant given the potential to treat other back-of-the-eye diseases.
Dr Ashton said the company was fortunate to have no debt with the prospect of significant royalty income in the short to medium term.
Last year pSivida raised $82 million from partner Alimera in exchange for increasing its equity stake in future treatment profits to 80 per cent.